

国内版

国际版



Dual targeting PLK1 and BIRC5 in TP53-mutated hepati



ALL

IMAGES

VIDEOS

12,300 Results

Any time ▼

### OCT4 increases BIRC5 and CCND1 expression and promotes ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583731>

Background. Recurrence and metastasis of **hepatocellular carcinoma** (HCC) depend on the persistent proliferative activity of **cancer** cells. **BIRC5**, also called Survivin, has been shown to play a pivotal role in cancers by influencing cell division and proliferation and by inhibiting apoptosis []. Many studies using clinical specimens have shown that **BIRC5** is invariably overexpressed in a ...

**Cited by:** 32

**Author:** Lu Cao, Chunguang Li, Shuwen Shen, Y...

**Publish Year:** 2013

### PLK1, A Potential Target for Cancer Therapy - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/S1936523316301371>

Polo-like kinase 1 (**PLK1**) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of **PLK1** may promote cancerous transformation and drive its progression. **PLK1** overexpression has been found in a variety of human cancers and was associated with poor prognoses in cancers. Many studies have showed that inhibition of **PLK1** could lead to death of **cancer** ...

**Cited by:** 81

**Author:** Zhixian Liu, Qingrong Sun, Xiaosheng ...

**Publish Year:** 2017

### PLK1/NF-κB feedforward circuit antagonizes the mono-ADP ...

<https://www.nature.com/articles/s41388-020-1205-8>

Feb 14, 2020 · Wright G, Golubeva V, Remsing Rix LL, Berndt N, Luo Y, Ward GA, et al. **Dual targeting** of WEE1 and **PLK1** by AZD1775 elicits single agent cellular anticancer activity. *Acs Chem Biol.* 2017;12:1883 ...

**Author:** Lantian Tian, Lantian Tian, Ke Yao, K... **Publish Year:** 2020

### Plk1-targeted therapies in TP53- or RAS-mutated cancer ...

<https://www.researchgate.net/publication/260806631> **Plk1-**



Dual targeting Polo-like kinase 1 and baculoviral inhibitor of apopto



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

9,120 Results

Any time ▾

[\(PDF\) Targeting polo-like kinase 1, a regulator of p53, in ...](#)

<https://www.researchgate.net/publication/290219417...>

Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.pdf

Bussey et al. Clin Trans Med (2016) 5:1 DOI 10.1186/s40169-015-0080-3

[332 - Gene ResultBIRC5 baculoviral IAP repeat containing 5 ...](#)

<https://www.ncbi.nlm.nih.gov/gene/332>

Jul 05, 2020 · This gene is a member of the **inhibitor of apoptosis** (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. IAP family members usually contain multiple baculovirus IAP repeat (BIR) domains, but this gene encodes proteins with only a single BIR domain. The encoded proteins also lack a C-terminus RING finger domain.

[PLK1 inhibition in cancer therapy: potentials and ...](#)

<https://www.future-science.com/doi/full/10.4155/fmc-2019-0084>

Jul 12, 2019 · Background. The last few decades have witnessed an evolving interest in **polo-like kinase 1** (PLK1) **inhibitors** as anticancer drugs [1]. Such interest was warranted by the overexpression of PLK1 in a broad range of cancers and its association with the poor prognosis of cancer, as well as the improved safety profile of PLK1 **inhibitors** versus classic mitotic **inhibitors** [2,3].

Cited by: 1

Author: Inas Elsayed, Xiaosheng Wang

Publish Year: 2019

[Polo-like kinase 1, a new therapeutic target in ...](#)

[https://www.researchgate.net/publication/229554675\\_Polo-like\\_kinase\\_1\\_a\\_new...](https://www.researchgate.net/publication/229554675_Polo-like_kinase_1_a_new...)

To investigate the role of **polo-like kinase 1** (PLK1) as a therapeutic target for **hepatocellular carcinoma** (HCC). PLK1 gene expression was evaluated in HCC tissue and HCC cell lines.

[Polo-like kinase \(Plk\)1 depletion induces apoptosis in ...](#)

<https://www.researchgate.net/publication/10772233...>

Depletion of the protein encoded by the **polo-like kinase 1** gene (PLK1) inhibits cancer cell proliferation and induces **apoptosis**; therefore, it is a target for cancer therapy (33). In this case ...

IJMS | Free Full-Text | Molecular Targeting of the ...



国内版 国际版



Dual targeting Polo-like kinase 1 and baculoviral inhibitor of apopto



ALL

IMAGES

VIDEOS

9,110 Results

Any time ▾

### Polo-like kinase 1, a new therapeutic target in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400854>

Jul 21, 2012 · AIM: To investigate the role of **polo-like kinase 1** (PLK1) as a therapeutic target for **hepatocellular carcinoma** (HCC). METHODS: PLK1 gene expression was evaluated in HCC tissue and HCC cell lines. Gene knockdown with short-interfering RNA (siRNA) was used to study PLK1 gene and protein expression using real-time reverse transcription polymerase chain reaction (RT ...

Cited by: 14

Author: Wei Chuen Mok, Shanthi Wasser, There...

Publish Year: 2012

### miRNA-125a-5p inhibits hepatocellular carcinoma cell ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601372>

Keywords: **hepatocellular carcinoma**, microRNA-125a-5p, TP53-regulated **inhibitor of apoptosis 1**, B cell lymphoma-2-like 2 protein, **apoptosis**, migration Introduction **Hepatocellular carcinoma** (HCC) is the sixth most common cancer worldwide, and is associated with almost half a million cases of mortality every year ( 1 ).

Cited by: 4

Author: Ma Ming, Ma Ying, Ma Ling

Publish Year: 2019

### (PDF) Targeting polo-like kinase 1, a regulator of p53, in ...

[https://www.researchgate.net/publication/290219417\\_Targeting\\_polo-like\\_kinase\\_1\\_a...](https://www.researchgate.net/publication/290219417_Targeting_polo-like_kinase_1_a...)

Targeting **polo-like kinase 1**, a regulator of p53, in the treatment of adrenocortical **carcinoma**.pdf  
Bussey et al. Clin Trans Med (2016) 5:1 DOI 10.1186/s40169-015-0080-3

### PLK1 inhibition in cancer therapy: potentials and ...

<https://www.future-science.com/doi/full/10.4155/fmc-2019-0084>

Jul 12, 2019 · Background. The last few decades have witnessed an evolving interest in **polo-like kinase 1** (PLK1) **inhibitors** as anticancer drugs [].Such interest was warranted by the overexpression of PLK1 in a broad range of cancers and its association with the poor prognosis of